Methimazole as a protectant against cisplatin-induced nephrotoxicity using the dog as a model.
The protective effect of methimazole, a commonly used antithyroid drug, on cisplatin-induced nephrotoxicity was studied. Eight dogs received 80 mg/m2 cisplatin i.v. without saline prehydration. Dogs were randomized into two groups of four dogs each: one group received 40 mg/kg methimazole i.p. at 30 min prior to and 4 h after cisplatin delivery, and the other group received saline placebo i.p. Methimazole protected dogs against the in vivo nephrotoxicity elicited by cisplatin as evidenced by clinicopathologic and histopathologic indices. Protection was not complete, as methimazole-treated animals developed mild histopathologic renal changes. Measures of renal oxidative stress did not differ between the two groups at day 5 following cisplatin treatment. No difference was noted for serum thyroxine concentrations before or after therapy in either group; however, serum levels of 3,5,3'-triiodothyronine were significantly higher on day 5 in both groups of dogs receiving cisplatin, regardless of whether they received methimazole or not. Methimazole as used in this study was found to be well tolerated in dogs over the short term, with no significant clinical or clinicopathologic toxicity being observed. The results of this study support the additional evaluation of methimazole as a protectant against cisplatin-induced nephrotoxicity using the dog as a model.
Vail
D M
DM
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison 53706.
Elfarra
A A
AA
Cooley
A J
AJ
Panciera
D L
DL
MacEwen
E G
EG
Soergel
S A
SA
D000818:Animals; D002945:Cisplatin / Q000009:adverse effects*; D004195:Disease Models, Animal; D004285:Dogs; D005978:Glutathione / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D008713:Methimazole / Q000627:therapeutic use*; D010084:Oxidation-Reduction; D010865:Pilot Projects; D011897:Random Allocation; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D014284:Triiodothyronine; D008713:Methimazole; D005978:Glutathione; D002945:Cisplatin; D013974:Thyroxine